Hana Pharm. Co., Ltd. Logo

Hana Pharm. Co., Ltd.

Pharmaceutical firm specializing in anesthetics and narcotic analgesics for global markets.

293480 | KO

Overview

Corporate Details

ISIN(s):
KR7293480000
LEI:
Country:
South Korea
Address:
경기도 화성시 향남읍 제약단지로 13-39, 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Hana Pharm Co., Ltd. is a pharmaceutical company specializing in the development, manufacturing, and distribution of specialty medicines. The company has a strong focus on anesthetics and narcotic analgesics, offering a comprehensive product portfolio that also includes antiemetics and antibiotics. Operating both domestically in South Korea and internationally, Hana Pharm is committed to innovation and quality, with significant investment in Good Manufacturing Practice (GMP) facilities. Its research and development pipeline includes novel products such as Byfavo Inj., an ultra-short-acting anesthetic and sedative, and a new multi-functional MRI contrast medium. The company went public in 2018 and continues to expand its market presence through ongoing research and strategic product development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-04 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 7.1 KB
2025-08-20 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 83.8 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-07-23 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 8.3 KB
2025-07-23 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2025-06-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-04-23 00:00
Regulatory News Service
신규시설투자등
Korean 8.4 KB
2025-03-24 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.8 KB
2025-03-14 00:00
Audit Report / Information
감사보고서제출
Korean 11.4 KB
2025-03-14 00:00
Annual / Quarterly Financial Statement
사업보고서 (2024.12)
Korean 501.3 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 158.7 KB
2025-02-28 00:00
Remuneration Information
기타경영사항(자율공시)
Korean 5.1 KB
2025-02-21 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 11.6 KB
2025-02-21 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정
Korean 9.0 KB

Automate Your Workflow. Get a real-time feed of all Hana Pharm. Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Hana Pharm. Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hana Pharm. Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.